Apple v. OpenAI, Google Gemini, Amazon, and AstraZeneca: Litigation Tracker

Coverage window: July 7-13, 2026. The strongest signals clustered around AI discovery and trade-secret disputes, while the pharma docket produced one clean Federal Circuit patent ruling. I am treating Nigeria's new platform-content investigation as a watch item rather than a main entry because it is regulatory, not yet a court case.

At a glance

Case	Sector	Current stage	Why it matters	Next milestone
Apple v. OpenAI, IO Products, Tang Tan, and Chang Liu	AI / hardware IP	New complaint filed in federal court in Northern California	Moves the AI competition fight from model training to consumer-device trade secrets	Defendants' first response deadline was not publicly reported 1
New York Times-led publishers v. OpenAI	AI copyright	Sanctions motion filed in SDNY discovery fight	Tests whether alleged search-log and chat-log gaps can produce adverse findings in AI copyright cases	Court ruling on sanctions; no hearing date was publicly reported 2
Thele et al. v. Google LLC	AI privacy / consumer protection	Complaint dismissed with leave to amend in N.D. Cal.	Clarifies the injury pleading burden for default-enabled AI assistant tracking claims	Plaintiffs have 21 days to amend 3
Horn v. Amazon.com Inc.	Tech platforms / consumer protection	Proposed class settlement filed in W.D. Wash.	Uses an assigned judgment structure to shift recovery efforts from Amazon to social-casino developers	Judicial approval of the settlement 4
AT&T pension class action	Tech / workplace benefits	Preliminary $184.1 million settlement filed in San Francisco federal court	Shows ERISA exposure from legacy actuarial assumptions at a major technology and telecom employer	Court approval; fee request may reach $35 million 5
Wyeth LLC v. AstraZeneca Pharmaceuticals LP	Pharma patent	Federal Circuit affirmed invalidity of Pfizer/Wyeth patents	Reinforces written-description and enablement limits in drug-patent enforcement	Mandate and any rehearing petition; no further date was reported 6

1. Apple sues OpenAI over consumer-hardware trade secrets

Parties. Apple sued OpenAI, IO Products, OpenAI hardware chief Tang Tan, and former Apple employee Chang Liu in federal court in Northern California on July 10. Apple says OpenAI used former Apple employees and business partners to obtain trade secrets for an AI consumer-hardware push. 1

Claims. The complaint alleges trade-secret theft tied to unreleased Apple technologies, processes, and products. CNBC quoted Apple's filing as saying OpenAI, "at every level," had been stealing Apple's trade secrets and confidential information. 1

Current stage. This is a newly filed complaint. CNBC reported that Apple is seeking damages, injunctions, and an order requiring OpenAI to stop using Apple's trade secrets. OpenAI said it has no interest in other companies' trade secrets. 1

Recent developments. Apple alleges that Tan directed Apple employees interviewing at OpenAI to bring "actual parts" from Apple to interviews, and that Liu stole an Apple laptop after joining OpenAI. Apple also claims OpenAI is asking hardware firms to carry out a metal-finishing technique that Apple invented. 1

Business impact. The case may become a discovery fight over recruiting, interview practices, prototype handling, and supplier instructions. That matters for every AI company trying to hire from device makers while moving into wearables, assistants, or ambient hardware.

Precedent value. The legal theory is familiar trade-secret law, but the competitive setting is new. If Apple survives early dismissal, hardware-focused AI labs may need tighter clean-room controls when hiring from incumbent device teams.

Next milestone. The first response deadline was not publicly reported. Watch for motions over forum, trade-secret identification, and whether Apple can define the alleged secrets with enough specificity before broad discovery.

2. Publishers seek sanctions against OpenAI in the Times copyright case

Parties. A group of newspapers led by the New York Times and New York Daily News asked a federal court in Manhattan on July 9 to sanction OpenAI in their copyright suit. The underlying case accuses OpenAI and Microsoft of using millions of news articles without permission to train ChatGPT. 2

Claims. The publishers say OpenAI falsely told the court it could not search its systems for copyrighted material, while hiding that it had performed such searches before the first news plaintiff filed suit. They also allege OpenAI deleted billions of relevant ChatGPT conversations or made them unsearchable. 2

Current stage. This is a discovery-sanctions motion, not a merits ruling. The publishers asked for attorneys' fees and for a court finding that OpenAI's chat logs showed misuse of their copyrighted works. 2

Recent developments. OpenAI said the allegations are false and argued that the Times is trying to invade the privacy of users unconnected to the case. Reuters also noted that the Times dropped a secondary copyright-infringement claim in an amended complaint filed last month. 2

Business impact. The motion goes to AI litigation infrastructure. If courts require model developers to preserve and search output logs at scale, discovery cost and privacy engineering become litigation-risk variables, not back-office details.

Precedent value. A sanctions order would matter beyond this case because many AI copyright suits turn on proof of training-data use, memorization, and output similarity. An adverse finding could let plaintiffs bypass some technical proof they otherwise would have to establish source by source.

Next milestone. The court must decide whether to grant sanctions, order further discovery, or reject the motion. No hearing date was publicly reported.

3. Google beats Gemini privacy claims, for now

Parties. Two Google users sued Google in the Northern District of California, alleging that Gemini tracked users' communications without knowledge or consent. The case is Thomas Thele et al. v. Google LLC, No. 5:25-cv-09704-NW. 3

Claims. The complaint alleged that Google violated user privacy by allowing Gemini to track communications by default rather than as an opt-in feature, and that Gemini could access and exploit emails and other records. 3

Current stage. U.S. District Judge Noel Wise dismissed the proposed class action on July 8, but gave the plaintiffs 21 days to amend. The judge held that the plaintiffs had not alleged that their own data had been affected by Gemini tracking. 3

Recent developments. The court said claims that Gemini could be used to track data were not enough by themselves. The plaintiffs described general categories of accessible account information, but did not allege that they observed their own data being used in targeted ads, personalized suggestions, or other service changes. 3

Business impact. The ruling gives AI-assistant providers a short-term standing and injury defense where plaintiffs plead only exposure to tracking, not concrete use or harm. It also tells plaintiffs exactly what kind of factual allegations they will try to add next.

Precedent value. This is not a final defeat for AI privacy claims. Its value is more precise: courts may demand user-specific allegations before letting broad default-activation theories move into class discovery.

Next milestone. Plaintiffs have 21 days from the July 8 order to amend. If they refile, the next question is whether they can plead a concrete data-use injury tied to Gemini rather than a platform-wide privacy concern.

Parties. Steven Horn sued Amazon.com in the Western District of Washington over social casino apps in the Amazon Appstore. The proposed settlement was filed on July 10 and requires court approval. 4

Claims. The 2023 class action alleged Amazon violated Washington gambling law and the state's consumer protection act by brokering transactions in social casino apps offered through the Amazon Appstore. Amazon has denied wrongdoing. 4

Current stage. Amazon would not pay a settlement fund. Instead, it would agree to a $201 million judgment against it, assign the class its rights to seek reimbursement from casino app developers, and receive a covenant that class members will not collect the judgment from Amazon. 4

Recent developments. Plaintiff lawyers said earlier social-casino developer settlements have returned more than $650 million to consumers. Reuters reported that parallel cases are pending against Apple, Google, and Meta, all of which deny wrongdoing. 4

Business impact. The settlement lets Amazon limit direct payment exposure while preserving a path for consumers to recover from developers. Platform operators should still read it as a warning: app-store transaction rails can be pleaded as participation in regulated activity, even when the contested product is built by a third party.

Precedent value. The structure may become a settlement template for marketplace and app-store cases. It separates platform liability posture from downstream developer reimbursement, which could shape parallel suits against Apple, Google, and Meta.

Next milestone. The settlement needs judicial approval. Any developer-recovery campaign would follow only if the court approves the deal.

5. AT&T moves to settle pension-equivalence claims for $184.1 million

Parties. AT&T agreed to pay $184.1 million to settle a proposed class action by about 300,000 current and former employees in San Francisco federal court. The preliminary settlement was filed on July 10 and requires a judge's approval. 5

Claims. The employees alleged AT&T violated ERISA by failing to provide married workers pension payments that were the actuarial equivalent of payments to single workers. They said AT&T used decades-old mortality data, resulting in lower payments to married workers. 5

Current stage. Under the settlement papers, employees would receive $149.1 million in additional pension benefits. Retired employees would receive $113.5 million, current employees $35.6 million, and class counsel may seek up to $35 million in fees and costs. 5

Recent developments. AT&T denied wrongdoing and said it settled to avoid the expense and distraction of prolonged litigation. The lawsuit began in October 2020. 5

Business impact. This is a workplace-benefits case, not a product case. It still belongs in the tracker because it shows how old actuarial assumptions can become nine-figure exposure for large technology and telecom employers with legacy benefit plans.

Precedent value. The settlement will not decide the merits, but it may push employers to audit pension conversion factors, spousal-benefit calculations, and mortality tables before plaintiffs' firms do it for them.

Next milestone. The court must decide whether to approve the settlement and any fee request. No approval hearing date was reported.

6. AstraZeneca keeps its win over Pfizer's Tagrisso patent claims

Parties. Pfizer subsidiary Wyeth sued AstraZeneca in 2021, alleging AstraZeneca's lung-cancer drug Tagrisso infringed patents related to the breast-cancer drug Nerlynx. The Federal Circuit case is Wyeth LLC v. AstraZeneca Pharmaceuticals LP, No. 24-2325. 6

Claims. Wyeth had won a $107.5 million Delaware jury verdict in 2024. U.S. District Judge Matthew Kennelly later overturned the verdict after finding the patents lacked valid written descriptions and would not enable an ordinary scientist to recreate the inventions without undue experimentation. 6

Current stage. The Federal Circuit affirmed the invalidity ruling on July 9. AstraZeneca therefore keeps its win against Pfizer's patent-infringement allegations. 6

Recent developments. Reuters reported that the appeals court agreed with the Delaware court on the same written-description and enablement grounds. Tagrisso generated more than $7.2 billion in global revenue last year, according to AstraZeneca reporting cited by Reuters. 6

Business impact. For drugmakers, the ruling tightens the link between patent drafting and enforcement value. A patent that reads broadly enough to reach a blockbuster therapy still has to teach the invention with enough detail to survive written-description and enablement attacks.

Precedent value. The case reinforces a Federal Circuit pattern that is especially important in life sciences: patents covering therapeutic classes or mechanisms can fail even after a jury verdict if the specification does not support the full asserted scope.

Next milestone. Watch for any rehearing petition or mandate activity. Reuters did not report a further date.

Watch points for the next cycle

OpenAI discovery pressure. The sanctions motion in the Times case will show whether AI defendants can keep privacy objections and technical search limits separate from evidence-preservation duties.
AI hardware recruiting. Apple's complaint may produce early fights over trade-secret identification and whether OpenAI's device work can be walled off from former Apple employees' knowledge.
Gemini amendment. The Google plaintiffs have a short window to turn a default-tracking theory into a user-specific injury theory.
Platform gambling exposure. The Amazon settlement approval process may influence parallel social-casino cases against Apple, Google, and Meta.
Pharma docket gap. The AstraZeneca ruling was the strongest pharma litigation signal in the checked sources this week. The next cycle should keep looking for drug-pricing, generic-entry, and FDA-related matters rather than forcing a weaker pharma entry.
Regulatory spillover. Nigeria's competition regulator opened an investigation into Meta, Alphabet, X, and generative AI platforms over alleged anti-competitive practices and unauthorized use of news content. It is not yet a lawsuit, but it could become a publisher-compensation or AI-training-content enforcement track to watch. 7

Apple v. OpenAI, Google Gemini, Amazon, and AstraZeneca: Litigation Tracker — Week of July 13